Seoul, South Korea

Ah-Jin Kim

USPTO Granted Patents = 1 


Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Profile of Inventor Ah-Jin Kim: Innovations in PPAR-Mediated Disease Treatment

Introduction: Ah-Jin Kim is an innovative inventor based in Seoul, South Korea. With a focus on improving health outcomes through scientific advancements, he has made significant contributions to the field of medical treatment.

Latest Patents: Ah-Jin Kim holds a patent for a method designed to treat conditions mediated by PPAR (peroxisome proliferator-activated receptor). His patent is titled "Method for treating conditions mediated by PPAR using macelignan." This method outlines the administration of macelignan, or its pharmaceutically acceptable salt, as an effective treatment for PPAR-mediated diseases, including diabetes mellitus.

Career Highlights: Currently, Ah-Jin Kim is part of Newtree Co., Ltd., where he actively engages in innovative research and development. His expertise in medicinal chemistry and his dedication to discovering new treatment options have earned him recognition in the industry.

Collaborations: Throughout his career, Ah-Jin has worked alongside talented colleagues, including Jae-Kwan Hwang and Kyu-Lee Han. These collaborations have contributed significantly to the advancement of their research initiatives and the successful development of innovative solutions in healthcare.

Conclusion: Ah-Jin Kim's contributions as an inventor are pivotal in the realm of medical treatments targeting PPAR-mediated conditions. Through his patent and collaborative efforts, he continues to push the boundaries of innovation, potentially improving the lives of many individuals suffering from metabolic diseases. His work exemplifies the impact of dedicated research and the importance of patenting innovative ideas that can lead to significant advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…